269 related articles for article (PubMed ID: 15872028)
1. Significant differential effects of lower doses of hormone therapy or tibolone on markers of cardiovascular disease in post-menopausal women: a randomized, double-blind, crossover study.
Koh KK; Han SH; Shin MS; Ahn JY; Lee Y; Shin EK
Eur Heart J; 2005 Jul; 26(14):1362-8. PubMed ID: 15872028
[TBL] [Abstract][Full Text] [Related]
2. Significant differential effects of hormone therapy or tibolone on markers of cardiovascular disease in postmenopausal women: a randomized, double-blind, placebo-controlled, crossover study.
Koh KK; Ahn JY; Jin DK; Yoon BK; Kim HS; Kim DS; Kang WC; Han SH; Choi IS; Shin EK
Arterioscler Thromb Vasc Biol; 2003 Oct; 23(10):1889-94. PubMed ID: 12933531
[TBL] [Abstract][Full Text] [Related]
3. The effect of continuous combined conjugated equine estrogen plus medroxyprogesterone acetate and tibolone on cardiovascular metabolic risk factors.
Skouby SO; Sidelmann JJ; Nilas L; Gram J; Jespersen J
Climacteric; 2008; 11(6):489-97. PubMed ID: 18991076
[TBL] [Abstract][Full Text] [Related]
4. Effects of conventional or lower doses of hormone replacement therapy in postmenopausal women.
Koh KK; Shin MS; Sakuma I; Ahn JY; Jin DK; Kim HS; Kim DS; Han SH; Chung WJ; Shin EK
Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):1516-21. PubMed ID: 15166013
[TBL] [Abstract][Full Text] [Related]
5. A comparative study of the effect of continuous combined conjugated equine estrogen plus medroxyprogesterone acetate and tibolone on blood coagulability.
Skouby SO; Sidelmann JJ; Nilas L; Jespersen J
Hum Reprod; 2007 Apr; 22(4):1186-91. PubMed ID: 17204528
[TBL] [Abstract][Full Text] [Related]
6. Effects of conjugated equine estrogens or raloxifene on lipid profile, coagulation and fibrinolysis factors in postmenopausal women.
Dias AR; Melo RN; Gebara OC; D'Amico EA; Nussbacher A; Halbe HW; Pinotti JA
Climacteric; 2005 Mar; 8(1):63-70. PubMed ID: 15804733
[TBL] [Abstract][Full Text] [Related]
7. Flow resistance in carotid and middle cerebral arteries in postmenopausal women: a comparative study of tibolone and continuous combined hormone replacement therapy.
Pan HA; Wang ST; Chen CH; Pai MC; Wu MH; Huang KE
Climacteric; 2002 Sep; 5(3):259-65. PubMed ID: 12419084
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of conventional and low dose oral hormone therapy (HT), tibolone, and raloxifene on coagulation and fibrinolysis.
Eilertsen AL; Sandvik L; Mowinckel MC; Andersen TO; Qvigstad E; Sandset PM
Thromb Res; 2007; 120(3):371-9. PubMed ID: 17156824
[TBL] [Abstract][Full Text] [Related]
9. Tibolone in postmenopausal women with systemic lupus erythematosus: a pilot study.
Vieira CS; Pereira FV; de Sá MF; Paulo LJ; Martins WP; Ferriani RA
Maturitas; 2009 Mar; 62(3):311-6. PubMed ID: 19193505
[TBL] [Abstract][Full Text] [Related]
10. Differential impact of conventional and low-dose oral hormone therapy (HT), tibolone and raloxifene on functionality of the activated protein C system.
Eilertsen AL; Liestøl S; Mowinckel MC; Hemker HC; Sandset PM
Thromb Haemost; 2007 Jun; 97(6):938-43. PubMed ID: 17549295
[TBL] [Abstract][Full Text] [Related]
11. Effect of conjugated equine estrogen in combination with two different progestogens on the risk factors of coronary heart disease in postmenopausal Chinese women in Taiwan: a randomized one-year study.
Chang TC; Lien YR; Chen M; Cheng SP; Chen RJ; Chow SN
Acta Obstet Gynecol Scand; 2004 Jul; 83(7):661-6. PubMed ID: 15225192
[TBL] [Abstract][Full Text] [Related]
12. Effect of hormone replacement therapy and tibolone on serum leptin levels in postmenopausal women.
Lambrinoudaki IV; Christodoulakos GE; Panoulis CP; Rizos DA; Dendrinos SG; Liakakos T; Augoulea AD; Creatsas GC
Maturitas; 2004 Jun; 48(2):107-13. PubMed ID: 15172084
[TBL] [Abstract][Full Text] [Related]
13. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women.
Zegura B; Guzic-Salobir B; Sebestjen M; Keber I
Menopause; 2006; 13(4):643-50. PubMed ID: 16837886
[TBL] [Abstract][Full Text] [Related]
14. Effect of different preparations of hormone therapy on lipid and glucose metabolism, coagulation factors, and bone mineral density in overweight and obese postmenopausal women.
Osmanağaoğlu MA; Osmanağaoğlu S; Osmanağaoğlu T; Okumuş B; Bozkaya H
Fertil Steril; 2005 Aug; 84(2):384-93. PubMed ID: 16084879
[TBL] [Abstract][Full Text] [Related]
15. Differential effect of hormone therapy and tibolone on lipids, lipoproteins, and the atherogenic index of plasma.
Christodoulakos GE; Lambrinoudaki IV; Economou EV; Papadias C; Panoulis CP; Kouskouni EE; Vlachou SA; Creatsas GC
J Cardiovasc Pharmacol; 2006 Apr; 47(4):542-8. PubMed ID: 16680067
[TBL] [Abstract][Full Text] [Related]
16. The effect of tibolone and continuous combined conjugated equine oestrogens plus medroxyprogesterone acetate on progression of carotid intima-media thickness: the Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study.
Bots ML; Evans GW; Riley W; McBride KH; Paskett ED; Helmond FA; Grobbee DE;
Eur Heart J; 2006 Mar; 27(6):746-55. PubMed ID: 16415304
[TBL] [Abstract][Full Text] [Related]
17. The differential effect of estrogen, estrogen-progestin and tibolone on coagulation inhibitors in postmenopausal women.
Keramaris NC; Christodoulakos GE; Lambrinoudaki IV; Dalamanga A; Alexandrou AP; Bramis J; Bastounis E; Creatsas GC
Climacteric; 2007 Oct; 10(5):400-7. PubMed ID: 17852143
[TBL] [Abstract][Full Text] [Related]
18. A 5-year study on the effect of hormone therapy, tibolone and raloxifene on vaginal bleeding and endometrial thickness.
Christodoulakos GE; Botsis DS; Lambrinoudaki IV; Papagianni VD; Panoulis CP; Creatsa MG; Alexandrou AP; Augoulea AD; Dendrinos SG; Creatsas GC
Maturitas; 2006 Mar; 53(4):413-23. PubMed ID: 16140483
[TBL] [Abstract][Full Text] [Related]
19. Tibolone for the treatment of moderate to severe vasomotor symptoms and genital atrophy in postmenopausal women: a multicenter, randomized, double-blind, placebo-controlled study.
Swanson SG; Drosman S; Helmond FA; Stathopoulos VM
Menopause; 2006; 13(6):917-25. PubMed ID: 17006377
[TBL] [Abstract][Full Text] [Related]
20. Circulating leptin and ghrelin are differentially influenced by estrogen/progestin therapy and raloxifene.
Lambrinoudaki IV; Christodoulakos GE; Economou EV; Vlachou SA; Panoulis CP; Alexandrou AP; Kouskouni EE; Creatsas GC
Maturitas; 2008 Jan; 59(1):62-71. PubMed ID: 18164562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
